;
Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Asunaprevir/daclatasvir/BMS-791325: Additional Phase II data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: Asunaprevir/daclatasvir/BMS-791325 Business: Infectious Molecular target: HCV NS3 protease; HCV NS5A protein Description: Fixed-dose oral combination of …

    Published on 4/14/2014
  • BioChaperone insulin combo: Final Phase I/II data

    Adocia S.A. (Euronext:ADOC), Lyon, France Product: BioChaperone insulin combo (BioChaperone Combo) Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Combination of long-acting insulin …

    Published on 4/14/2014
  • BioChaperone Lispro: Phase IIa data

    Adocia S.A. (Euronext:ADOC), Lyon, France Product: BioChaperone Lispro Business: Endocrine/Metabolic Molecular target: Insulin receptor (INSR) Description: Ultra-fast acting formulation of insulin lispro using …

    Published on 4/14/2014
  • CT327: Additional Phase IIb data

    Creabilis S.A., Luxembourg, Luxembourg Product: CT327 (formerly CT 301/P) Business: Autoimmune Molecular target: Neurotrophic tyrosine kinase receptor 1 (NTRK1) (TrkA) Description: Topical neurotrophic tyrosine kinase …

    Published on 4/14/2014
  • Dexanabinol: Interim Phase Ia data

    e-Therapeutics plc (LSE:ETX), Long Hanborough, U.K. Product: Dexanabinol (ETS2101) Business: Cancer Molecular target: Not available Description: Small molecule chemotherapeutic synthetic cannabinoid Indication: Treat …

    Published on 4/14/2014
  • Eloctate: Phase III data

    Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Swedish Orphan Biovitrum AB (SSE:SOBI), Stockholm, Sweden Product: Eloctate (Long-lasting rFACTOR VIII, RFVIIIFc) Business: Hematology Molecular target: Factor VIII …

    Published on 4/14/2014
  • Galactoarabino-rhamnogalacturonate: Phase I data

    Galectin Therapeutics Inc. (NASDAQ:GALT), Norcross, Ga. Product: Galactoarabino-rhamnogalacturonate (GR-MD-02) Business: Hepatic Molecular target: Galectin-3 (LGALS3); Galectin-1 (LGALS1) Description: Galectin-3 (LGALS3…

    Published on 4/14/2014
  • IDX21437: Phase I/II data

    Idenix Pharmaceuticals Inc. (NASDAQ:IDIX), Cambridge, Mass. Product: IDX21437 Business: Infectious Molecular target: HCV NS5B polymerase Description: Uridine nucleotide analog HCV NS5B polymerase inhibitor Indication: …

    Published on 4/14/2014
  • Lexaptepid pegol: Phase IIa data

    Noxxon Pharma AG, Berlin, Germany Product: Lexaptepid pegol (NOX-H94) Business: Hematology Molecular target: Hepcidin Description: L-aptamer hepcidin inhibitor Indication: Treat anemia Endpoint: Anemia response rate; …

    Published on 4/14/2014
  • MK-5172: Additional Phase II data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: MK-5172 Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Oral HCV NS3/4A protease complex inhibitor Indication: Treat chronic…

    Published on 4/14/2014
  • MK-5172: Phase II data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: MK-5172 Business: Infectious Molecular target: HCV NS3/4A protease complex Description: Oral HCV NS3/4A protease complex inhibitor Indication: Treat chronic…

    Published on 4/14/2014
  • MK-8742: Additional Phase II data

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Product: MK-8742 Business: Infectious Molecular target: HCV NS5A protein Description: Oral HCV NS5A protein inhibitor Indication: Treat chronic HCV genotype 1 …

    Published on 4/14/2014
  • NW-3509: Preliminary Phase I data

    Newron Pharmaceuticals S.p.A. (SIX:NWRN), Bresso, Italy Product: NW-3509 Business: Neurology Molecular target: Sodium channel Description: Voltage-gated sodium channel inhibitor Indication: Treat schizophrenia Endpoint:…

    Published on 4/14/2014
  • Oral neratinib: Additional Phase II data

    Puma Biotechnology Inc. (NYSE:PBYI), Los Angeles, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Oral neratinib (HKI-272, PB272) Business: Cancer Molecular target: Epidermal growth factor receptor 1 (EGFR1) (…

    Published on 4/14/2014
  • Palbociclib: Additional Phase II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Palbociclib (PD-0332991) Business: Cancer Molecular target: Cyclin dependent kinase 4 (CDK4); Cyclin dependent kinase 6 (…

    Published on 4/14/2014
  • PEG-IFN lambda: Phase IIb data

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Product: PEG-IFN lambda (peginterferon lambda) (PEG-rIL-29) Business: Infectious Molecular target: Interleukin-29 (IL-29) (IFNL1) Description: Pegylated recombinant IL…

    Published on 4/14/2014
  • PulmoXen: Phase I data

    Xenetic Biosciences Inc. (OTCBB:XBIO), London, U.K. Pharmsynthez JSC (MICEX:LIFE), St. Petersburg, Russia Product: PulmoXen, Bronchozym Business: Pulmonary Molecular target: DNA Description: Inhaled polysialylated …

    Published on 4/14/2014
  • Votrient pazopanib: Phase IIIb data

    GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Votrient pazopanib Business: Cancer Molecular target: Vascular endothelial growth factor (VEGF) receptor 1 (FLT1) (VEGFR-1); Vascular endothelial growth …

    Published on 4/14/2014
  • VT-1161: Interim Phase IIa data

    Viamet Pharmaceuticals Inc., Morrisville, N.C. Product: VT-1161 Business: Infectious Molecular target: Cytochrome P450 C-14 alpha demethylase (CYP51) Description: Small molecule metalloenzyme inhibitor of cytochrome …

    Published on 4/14/2014
  • Xeljanz tofacitinib: Additional Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Xeljanz tofacitinib (Jaquinus) (CP-690,550) (formerly tasocitinib) Business: Autoimmune Molecular target: Janus kinase-3 (JAK-3); Janus kinase-1 (JAK-1) Description: Oral …

    Published on 4/14/2014
  • AbobotulinumtoxinA: Phase IIa data

    Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: AbobotulinumtoxinA (Dysport) (formerly Reloxin) Business: Genitourinary Molecular target: NA Description: Injectable formulation of botulinum…

    Published on 4/7/2014
  • Alirocumab: Additional Phase III data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 4/7/2014
  • Alirocumab: Extension study data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 4/7/2014
  • Alirocumab: Phase II data

    Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Alirocumab (SAR236553, REGN727) Business: Endocrine/Metabolic Molecular target: Proprotein convertase…

    Published on 4/7/2014
  • Artemether: Preliminary Phase III data

    LondonPharma Ltd., Norwich, U.K. Suda Ltd. (ASX:SUD), Osborne Park, Australia Product: Artemether (ArTiMist) Business: Infectious Molecular target: NA Description: Sublingual aerosol formulation of artemisinin …

    Published on 4/7/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993